Icahn Sch of Med at Mt. Sinai

New York, New York 10029

0 studies enrolling now · 4 studies all time

What they study most

Atopic Dermatitis, Ulcerative Colitis

Studies at this site

• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC) — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) — Completed
• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis — Stopped early